Page last updated: 2024-08-24

irinotecan and Disease Exacerbation

irinotecan has been researched along with Disease Exacerbation in 361 studies

Research

Studies (361)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (1.94)	18.2507
2000's	184 (50.97)	29.6817
2010's	146 (40.44)	24.3611
2020's	24 (6.65)	2.80

Authors

Authors	Studies
Akouz, FK; Barbier, E; Bourgeois, V; Coriat, R; Dahan, L; Desrame, J; Edeline, J; Ghiringhelli, F; Lecomte, T; Louafi, S; Ly, VL; Malka, D; Manfredi, S; Michel, P; Molin, Y; Neuzillet, C; Perrier, H; Phelip, JM; Soularue, E; Terrebonne, E	1
Besselink, MG; Bonsing, BA; Bosscha, K; de Groot, JWB; Groot Koerkamp, B; Haberkorn, BCM; Homs, MYV; Karsten, TM; Luelmo, SAC; Mekenkamp, LJM; Mustafa, DAM; van Bekkum, ML; van den Bosch, TPP; van der Sijde, F; van Eijck, CHJ; Vietsch, EE; Wilmink, JW	1
Boku, N; Esaki, T; Izawa, N; Kawakami, K; Kawakami, T; Komoda, M; Makiyama, A; Masuishi, T; Mitani, S; Moriwaki, T; Nagashima, K; Nakajima, TE; Okuda, H; Tsuji, Y; Yamamoto, S; Yamamoto, Y; Yamazaki, K	1
Adenis, A; Al-Rajabi, R; Amonkar, M; Bhagia, P; de la Fouchardiere, C; Girotto, GC; Kulkarni, AS; Mansoor, W; Metges, JP; Norquist, J; Senellart, H; Suryawanshi, S; van Laarhoven, HWM	1
Dong, S; Gu, J; Guo, W; Huang, Y; Ren, T; Sun, K; Sun, X; Tang, X; Xie, L; Xu, J; Yang, F; Yang, R	1
Baek, SE; Chung, HC; Han, Y; Hong, M; Jeung, HC; Jung, M; Kim, CG; Kim, H; Kim, HS; Kim, JH; Lee, CK; Lee, G; Lee, JH; Lee, SY; Rha, SY; Shin, SJ	1
Berres, ML; Gonzalez-Carmona, M; Kehmann, L; Keitel, V; Luedde, T; Modest, DP; Mohr, R; Roderburg, C; Strassburg, C; Trautwein, C; Venerito, M; Wree, A	1
Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y	1
Aparicio, T; Ben Abdelghani, M; Blons, H; Boige, V; Bouché, O; Brument, E; Castan, F; De La Fouchardière, C; François, E; Galais, MP; Genet, D; Gourgou, S; Hautefeuille, V; Jacquot, S; Le Brun-Ly, V; Levaché, CB; Levasseur, N; Miglianico, L; Mineur, L; Mitry, E; Penel, N; Phelip, JM; Villing, AL	1
Chen, X; He, Q; Li, M; Liu, Y; Sheng, Q; Shi, K; Wang, Y; Yu, Q; Zhang, Z	1
Anderson, L; Arkenau, HT; Braun, M; Calvo Ferrandiz, A; Christy-Bittel, J; Ciardiello, F; Dekervel, J; Desai, J; Elez, E; Garcia-Alfonso, P; Gollerkeri, A; Grothey, A; Guo, C; Guren, TK; Hong, YS; Keir, C; Kim, TW; Kopetz, S; Krishnan, A; Lonardi, S; Loupakis, F; Maharry, K; Morris, V; Orlov, S; Pfeiffer, P; Pickard, M; Sandor, V; Schellens, JHM; Steeghs, N; Tabernero, J; Tarpgaard, LS; Van Cutsem, E; Wasan, H; Yaeger, R; Yoshino, T	1
Cao, Y; Li, Q; Liu, Y; Zhang, Y; Zhou, J	1
Chen, X; Han, W; Li, Y; Shi, L; Wan, J; Wang, H; Xie, B	1
Bang, JH; Bang, YJ; Jin, MH; Nam, AR; Oh, DY; Park, H; Park, JE	1
Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS	1
Bapat, B; Brown, J; Candrilli, SD; García-Foncillas, J; Kaye, JA; Liepa, AM; Lorenzen, S; Madhwani, S	1
Cid, NG; Labandeira, CM; Manrique, MCA; Mata, JG; Montes, AF; Núñez, MÁ; Ron, DA; Vera, R	1
Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D	1
Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B	1
Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S	1
Camara, JC; Franco, F; Gutiérrez-Abad, D; Juez, I; León, A; López-Alfonso, A; Marrupe, D; Martín-Valadés, JI; Martínez-Amores, B; Pérez, M; Royuela, A; Ruiz-Casado, A	1
Li, C; Li, X; Li, Z; Liu, Y; Ma, Y; Qi, Y; Wu, G; Yin, M; Zeng, Y; Zhao, Y	1
Cui, J; Qu, S; Wang, L; Zhang, X	1
Lovetrue, B	1
Asagi, A; Furuse, J; Horiguchi, S; Ikeda, M; Imaoka, H; Kasuga, A; Kobayashi, S; Kojima, Y; Morizane, C; Nagashio, Y; Ozaka, M; Shiba, S; Shioji, K; Suzuki, E; Takada, R; Takahashi, H; Terashima, T; Todaka, A; Ueno, M; Yane, K	1
Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Freiberg-Richter, J; Giessen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Michl, M; Modest, DP; Peuser, B; Ricard, I; Schenk, M; Stahler, A; Stintzing, S; Uhlig, J	1
Abdallah, R; Auclin, E; Bachet, JB; Coriat, R; Cunha, AS; de La Fouchardière, C; Fabiano, E; Forestier, J; Francois, E; Hautefeuille, V; Ksontini, F; Lecomte, T; Leroy, F; Marthey, L; Mas, L; Saint, A; Sarabi, M; Taieb, J; Tougeron, D; Vienot, A; Williet, N	1
Custodio, A; Feliu, J; Garcia-Cuesta, JA; Ghanem, I; Gutierrez-Sainz, L; Martinez-Perez, D; Villamayor, J; Viñal, D	1
Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y	1
Adam, R; Barroso, E; Capussotti, L; Elias, D; Giuliante, F; Gruenberger, T; Guglielmi, A; Hubert, C; Innominato, PF; Isoniemi, H; Lapointe, R; Laurent, C; Lin, JK; Lopez-Ben, S; Regimbeau, JM; Skipenko, OG; Yi, B	1
Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW	1
Berlin, JD; Cohen, SJ; Dotan, E; Goldberg, RM; Goldenberg, DM; Govindan, SV; Guarino, MJ; Hecht, JR; Lieu, CH; Marshall, JL; Messersmith, WA; Sharkey, RM; Simpson, PS; Starodub, AN; Wegener, WA	1
Artioli, M; Braghiroli, MI; Braghiroli, OFM; Costa, FP; Fernandes, GDS; Girardi, DDM; Gumz, BP; Hoff, PM; Paterlini, ACCR; Teixeira, MC	1
Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA	1
Eisterer, W; Fridrik, MA; Greil, R; Gruenberger, B; Hejna, M; Huemer, F; Keil, F; Thaler, J; Trommet, V; Ulmer, H; Weiss, L; Wöll, E	1
Carnaghi, C; Cimino, M; Darwish, SS; Del Fabbro, D; Donadon, M; Personeni, N; Procopio, F; Rimassa, L; Santoro, A; Torzilli, G; Vigano, L	1
Kellett, C; Kim, CA; Lambert, P; Zhang, H	1
Hu, T; Li, Q; Liu, C; Ma, Y; Wu, G; Xiong, J; Zhao, Y	1
Ahn, JB; Elme, A; Guan, X; Jung, AS; Kim, SY; Kim, TW; Krishnan, S; Lofton-Day, C; Manojlovic, N; Park, JO; Udrea, AA; Valencia, RV; Vrdoljak, E	1
Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M	1
Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC	1
Assi, H; Charafeddine, M; Hammoud, MS; Makki, I; Mukherji, D; Nassif, S; Shamseddine, A; Temraz, S; Tfayli, A	1
Adenis, A; Artru, P; Bennouna, J; Bertaut, A; Borel, C; Borg, C; Bouché, O; Conroy, T; Denis, MG; Deplanque, G; des Guetz, G; François, E; Ghiringhelli, F; Hebbar, M; Hiret, S; Seitz, JF; Stanbury, T	1
Becker, C; Belanger, B; Blanc, JF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Mamlouk, K; Melisi, D; Siveke, JT; Von Hoff, DD; Wang-Gillam, A; Yang, Y	1
Aprile, G; Barbara, C; Barone, C; Bergamo, F; Busico, A; Conca, E; Corsi, DC; Cremolini, C; Danesi, R; Del Re, M; Dell'Aquila, E; Falcone, A; Lonardi, S; Masi, G; Pantano, F; Pella, N; Pietrantonio, F; Pucci, F; Rofi, E; Rossini, D; Santini, D; Tamburini, E	1
Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E	1
Nazha, B; Owonikoko, TK	1
Algül, H; Atzpodien, J; Berger, AW; Daum, S; Dickhut, A; Ettrich, TJ; Gallmeier, E; Geissler, M; König, A; Kornmann, M; Muche, R; Perkhofer, L; Prasnikar, N; Reinacher-Schick, A; Seufferlein, T; Tannapfel, A; Uhl, W; Wille, K; Wittel, U	1
Hui, SC; Kang, C; Lang, HD; Mi, MT; Wang, XL; Yi, L; Zhang, Y; Zhou, M; Zhu, XH	1
Asakuma, M; Gonen, M; Haeno, H; Hur, C; Inoue, Y; Kartoun, U; Kong, CY; Liu, LL; Michor, F; Nakamura, A; Shimizu, T; Stein, S; Tramontano, AC; Uchiyama, K; Yamamoto, KN	1
Akinwande, O; Malone, C; Mokkarala, M; Noda, C; Ramaswamy, R	1
Byun, Y; Choi, YJ; Han, Y; Jang, JY; Kang, JS; Kim, H; Kim, SW; Kim, YT; Kwon, W; Lee, SH; Oh, DY; Ryu, JK	1
Doki, Y; Haraguchi, N; Hata, T; Kudo, T; Matsuda, C; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Takahashi, H; Takemasa, I	1
Bang, JH; Bang, YJ; Eun Park, J; Hua Jin, M; Nam, AR; Oh, DY; Park, H	1
Auby, D; Bouché, O; Ducreux, M; Etienne, PL; Michiels, S; Pénichoux, J; Pignon, JP; Rougier, P; Texereau, P	1
Andersen, RF; Havelund, BM; Jakobsen, AK; Lassen, U; Pallisgaard, N; Ploen, J; Sorensen, MM; Spindler, KL	1
Fukuhara, T; Inoue, A; Ishimoto, O; Maemondo, M; Matsubara, N; Morikawa, N; Nukiwa, T; Sakakibara, T; Sugawara, S; Tanaka, M; Watanabe, K	1
Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E	1
Gao, J; Gong, JF; Li, J; Li, Y; Lu, M; Lu, ZH; Shen, L; Wang, XC; Zhang, XT; Zhou, J	1
Lam, VW; Laurence, JM; Richardson, AJ	1
Dunne, DF; Fenwick, SW; Jones, RP; Malik, HZ; O'Grady, E; Poston, GJ; Smethurst, A; Stättner, S; Terlizzo, M	1
Blasius, E; Boström, J; Glas, M; Greschus, S; Herrlinger, U; Kebir, S; Landwehr, C; Mack, F; Rasch, K; Schäfer, N; Schaub, C; Scheffler, B; Seifert, M; Simon, M; Stuplich, M; Urbach, H; Vilz, B; Waha, A	1
Anghileri, E; Bertolini, F; Bruzzone, MG; Calleri, A; Ceroni, M; Cuppini, L; Di Stefano, AL; Eoli, M; Finocchiaro, G; Mancuso, P; Pellegatta, S; Porrati, P; Prodi, E	1
Albert-Mari, A; Jimenez-Torres, NV; Ruiz-Millo, O; Sendra-Garcia, A	1
Jiang, W; Li, Y; Liu, J; Ma, D; Yang, D	1
Adenis, A; Assenat, E; Bennouna, J; Bibeau, F; Boissière, F; Bouché, O; Conroy, T; Crapez, E; Desseigne, F; Francois, E; Galais, MP; Laurent-Puig, P; Mazard, T; Poujol, S; Samalin, E; Seitz, JF; Taieb, J; Thézenas, S; Ychou, M	1
Buonadonna, A; Caggiari, L; Cecchin, E; D' Andrea, M; De Re, V; De Zorzi, M; Innocenti, F; Racanelli, V; Talamini, R; Toffoli, G; Zagonel, V	1
Egle, A; Greil, R; Grundbichler, M; Hufnagl, C; Magnes, T; Melchardt, T; Moik, M; Strasser, M; Weiss, L	1
Bendell, JC; Berlin, JD; El-Rayes, BF; George, TJ; Hart, LL; Kingsley, CD; Lenz, HJ; Marshall, JL; Modiano, MR; Nakashima, D; Ryan, T	1
Boige, V; Dias, MM; Glimelius, B; Karapetis, CS; Kweekel, DM; Lara, PN; Laurent-Puig, P; Martinez-Balibrea, E; McKinnon, RA; Páez, D; Pignon, JP; Punt, CJ; Redman, MW; Sorich, MJ; Toffoli, G; Wadelius, M	1
Anders, HJ; Frese, S; Frese-Schaper, M; Gugger, M; Huynh-Do, U; Keil, A; Kocher, GJ; Körner, M; Schiffer, L; Schmid, RA; Steiner, SK	1
Cao, Y; Gong, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Wu, Y; Zhang, X; Zhou, J	1
Arao, T; Hamaguchi, T; Hayashi, H; Hirashima, Y; Honma, Y; Horita, Y; Iwasa, S; Kato, K; Kimura, H; Matsumoto, K; Nakagawa, K; Nishio, K; Okita, NT; Shimada, Y; Takashima, A; Togashi, Y; Yamada, Y	1
Hendel, HW; Høgdall, EV; Jensen, BV; Johannesen, HH; Nielsen, D; Schou, JV; Skougaard, K	1
Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY	1
Goldberg, RM; Gray, E; Karrison, TG; Sargent, DJ; Sharma, MR	1
Chow, L; DeWire, M; Fouladi, M; Goldman, S; Hummel, T; Lane, A; Leach, J; Miles, L; Salloum, R; Stevenson, C; Sutton, M	1
Arnold, D; Bhargava, P; Chevalier, S; Cunningham, D; Ferry, DR; Hoff, PM; Lakomỳ, R; Macarulla, T; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Ten Tije, AJ; Van Cutsem, E; Van Hazel, GA; Vishwanath, RL	1
Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY	1
Komune, S; Nakashima, T; Toh, S; Yamauchi, M; Yasumatsu, R	1
Bengrine, L; Ghiringhelli, F; Guion-Dusserre, JF; Lorgis, V; Vincent, J	1
André, T; Buyse, M; Delbaldo, C; Douillard, JY; Dupuis, O; Faroux, R; Guerin-Meyer, V; Jouhaud, A; Piedbois, P; Quinaux, E; Rougier, P; Ychou, M; Zawadi, A	1
Akamaru, Y; Fujitani, K; Inagaki, H; Ishiguro, T; Miyashita, Y; Morita, S; Nakamura, M; Nishikawa, K; Sakamoto, J; Shigematsu, T; Sugimoto, N; Takagi, M; Tamura, S; Tokunaga, S; Tsuburaya, A; Tsujinaka, T; Yoshikawa, T	1
Del Rio, M; Gongora, C; Jin, C; Lam, H; Li, F; Ling, X; Wani, M; Welch, J; Westover, D	1
Dalla Pozza, L; Heath, JA; Kalra, M; Kellie, SJ; McCowage, GB; Stevens, MM; Swamy, S	1
Aparicio, T; Des Guetz, G; Landre, T; Mary, F; Nicolas, P; Taleb, C; Uzzan, B; Zelek, L	1
Bowman, KJ; Jones, GD; Smith, AJ; Thomas, AL; Wood, JP	1
Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M	1
Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G	1
Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Ryu, JK	1
Arzt, J; Busman, TA; Holen, KD; Lian, G; LoRusso, P; Rosen, LS; Rudersdorf, NS; Tolcher, AW; Vanderwal, CA; Waring, JF; Yang, J	1
Anderson, JR; Arndt, CA; Hawkins, DS; Lyden, E; Meyer, WH; Michalski, JM; Parham, DM; Rodeberg, DA; Weigel, BJ	1
Fujiwara, H; Ikai, A; Kishimoto, M; Otsuji, E; Sakai, T; Sowa, Y; Watanabe, M; Yanagisawa, A	1
Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L	1
Bai, X; Gao, S; Li, G; Liang, T; Lou, J; Ma, T; Que, R; Shen, S; Su, R; Wei, Q; Yu, R; Yuan, Y	1
André, N; Dory-Lautrec, P; Figarella-Branger, D; Gentet, JC; Heng, MA; Padovani, L; Pasquier, E; Scavarda, D; Verschuur, A	1
Diaz-Serrano, A; Garcia-Carbonero, R; Riesco-Martinez, MC	1
Benson, AB; Burtness, BA; Cohen, SJ; Douglas, K; Enzinger, PC; Goldberg, RM; Ilson, DH; Mayer, RJ; Niedzwiecki, D; Venook, A; Villaflor, VM; Ye, X	1
Ball, A; Bowers, M; Bridgewater, JA; Corkhill, A; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Maishman, T; Maughan, TS; O'Reilly, DA; Primrose, JN; Pugh, SA; Radford, M; Rees, C; Rees, M; Siriwardena, AK; Stanton, L; Valle, JW	1
Alcaide, J; Díez de Corcuera, I; Feliu, J; García García, T; Manzano, JL; Sastre, J; Valladares-Ayerbes, M; Vera, R	1
Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K	1
Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M	1
Fan, WF; Meng, LJ; Pu, XL; Wang, J; Yang, M	1
Akamatsu, H; Furukawa, K; Ikehara, M; Kishi, K; Koh, M; Masuzawa, T; Suzuki, Y; Tanemura, M; Tei, M; Tsukada, R	1
Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL	1
Adamo, V; Battistoni, F; Dicuonzo, G; Fulfaro, F; Galluzzo, S; Rocci, L; Russo, A; Santini, D; Silletta, M; Tonini, G; Vincenzi, B; Zobel, BB	1
Banzi, C; Biasco, G; Bonetti, F; Boni, C; Brandes, A; Calandri, C; Carandina, I; Cataldo, S; DI Fabio, F; Lelli, G; Marzola, M; Nanni, O; Negri, F; Panetta, A; Pantaleo, MA; Ravaioli, E; Turci, D; Urbini, B	1
Cianci, G; Cortesi, E; D'Auria, G; Gamucci, T; Grassi, G; Moscetti, L; Nelli, F; Pollera, CF; Sperduti, I; Zeuli, M	1
Cole, BF; Eskey, CJ; Fadul, CE; Kingman, LS; Meyer, LP; Newton, HB; Pipas, JM; Rhodes, CH; Roberts, DW	1
Brell, JM; Dowlati, A; Ivy, SP; Javle, M; Kantharaj, BN; Krishnamurthi, SS; Pelley, R; Rath, L; Remick, SC; Saltzman, J; Schluchter, MD; Wollner, I	1
Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD	1
Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ	1
Bodoky, G; Garay, C; Habboubi, N; Haller, DG; Koralewski, PM; Miller, WH; Olivatto, LO; Rothenberg, ML; Wong, AO	1
Berardi, R; Cascinu, S; Chiorrini, S; Galizia, E; Giampieri, R; Pierantoni, C; Scartozzi, M	1
Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J	1
Aapro, MS; Adenis, A; Aguilar, EA; Esser, R; Glynne-Jones, R; Loos, AH; Preusser, P; Siena, S; Thaler, J; Wilke, H	1
Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Tsuchida, K	1
Grunnet, K; Hasselbalch, B; Kosteljanetz, M; Lassen, U; Nelausen, K; Olsen, P; Poulsen, HS; Sorensen, M	1
Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S	1
Balzer, JO; Eichler, K; Gruber, T; Hammerstingl, R; Vogl, TJ; Zangos, S	1
Assersohn, L; Brown, G; Chong, G; Costello, C; Cunningham, D; Higgins, L; Leary, A; Norman, AR; Oates, J; Ross, PJ	1
Chin, K; Hatake, K; Konishi, F; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Suenaga, M; Ueno, M; Yamaguchi, T	1
Ilson, DH; Kelsen, DP; Ku, GY; Maki, RG; O'Reilly, EM; Saltz, LB; Schrag, D	1
Ahn, JS; Ahn, MJ; Chang, MH; Hwang, IG; Ji, SH; Jun, HJ; Kim, HS; Kim, KH; Lee, J; Lim, DH; Park, K; Park, MJ; Park, YH; Uhm, JE; Yi, SY	1
Cohen, SJ; Doyle, GV; Gabrail, NY; Iannotti, N; Meropol, NJ; Miller, MC; Mitchell, E; Morse, MA; Picus, J; Punt, CJ; Sabbath, KD; Saidman, BH; Terstappen, LW; Tissing, H	1
Aoun, N; Baz, W; Burton, J; El-Soueidi, R; Forte, F; Lowry, J; Nakhl, F	1
Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL	1
Sobrero, A	1
Burtness, B; Egleston, B; Forastiere, AA; Gibson, M; Lacy, J; Mehra, R; Murren, JR; Quintanilla, M; Sipples, R; Thomas, L; Watkins, S	1
Fujii, S; Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Oota, Y; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Souda, M; Tanaka, K; Yamamoto, Y	1
Addeo, R; Baldi, GG; Del Prete, S; Di Fabio, F; Falcone, A; Loupakis, F; Pinto, C; Rojas Llimpe, FL; Santini, D; Tonini, G; Vincenzi, B	1
Chang, HJ; Han, HS; Hong, YS; Jung, KH; Kim, SY; Lee, KS	1
Saltz, LB; Segal, NH	1
Koopman, M; Mol, L; Ottevanger, PB; Punt, CJA	1
Bodnar, L; Stec, R; Szczylik, C	1
Endo, M; Igawa, S; Ito, I; Kaira, K; Kameya, T; Murakami, H; Naito, T; Nakamura, Y; Takahashi, T; Tsuya, A; Watanabe, R; Yamamoto, N	1
Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G	1
Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS; Zhang, L	1
An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH	1
Cunningham, D; Yim, KL	1
Boeck, S; Giessen, C; Heinemann, V; Moosmann, N; Schalhorn, A; Schulz, C; Stemmler, HJ; Zwingers, T	1
Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R	1
Carrie, C; de la Fouchardière, C; Desseigne, F; Labrosse, H; Martel Lafay, I; Méeus, P; Négrier, S; Pérol, D; Petit-Laurent, F; Rivoire, M; Tavan, D	1
Chang, PY; Cheng, MF; Hsieh, CB; Lee, HS; Yao, NS	1
Cho, EK; Jung, SH; Kim, YS; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ	1
Brendel, E; Laferriere, N; Langenberg, MH; Mergui-Roelvink, M; Roodhart, JM; Schellens, JH; van der Sar, J; Verheul, HM; Voest, EE; Witteveen, PO	1
Choi, SK; Ha, CY; Ju, YT; Kang, JH; Kim, HG; Kwon, HC; Lee, GW; Lee, WS; Oh, SY	1
Arango, D; Armengol, M; Bazzocco, S; Carreras, MJ; Dopeso, H; Elez, E; Espín, E; Hernández-Losa, J; Landolfi, S; Mariadason, JM; Mateo-Lozano, S; Mazzolini, R; Ramon Y Cajal, S; Ramos Pascual, FJ; Rodrigues, P; Schwartz, S; Tabernero, J; Wilson, AJ	1
Hatayama, S; Honda, T; Kagabu, M; Kaido, Y; Kumagai, S; Miura, F; Morohara, Y; Murai, M; Omi, H; Satoh, A; Shoji, T; Sugiyama, T; Takatori, E; Yoshizaki, A	1
Goldberg, RM	1
Bai, J; Chen, J; Duanmu, Z; Gong, Y; Huang, H; Tang, C; Yang, J; Zhou, B; Zhuang, L	1
Fushimi, K; Kumagai, K; Nakano, S; Yamamoto, N	1
Aranda, E; Bandrés, E; Boni, V; Garcia-Foncillas, J; Gomez, MA; Maiello, E; Villa, JC; Zarate, R	1
Chen, W; Gadgeel, SM; Kalemkerian, GP; Kraut, MJ; Ramnath, N; Ruckdeschel, JC; Schneider, BJ; Worden, FP; Wozniak, AJ; Zhang, X	1
Hamaguchi, T; Hirashima, Y; Kato, K; Nishitani, H; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Takeshita, S; Yamada, Y	1
Georgoulias, V; Giassas, S; Gioulbasanis, I; Kalbakis, K; Kontopodis, E; Samonis, G; Vardakis, N; Varthalitis, I; Xenidis, N; Ziras, N	1
Anderson, JR; Breitfeld, PP; Donaldson, SS; Hawkins, DS; Lyden, ER; Mascarenhas, L; Meyer, WH; Paidas, CN; Parham, DM; Walterhouse, DO	1
Breithaupt, K; Thuss-Patience, PC	1
Dosa, E; Kraemer, DF; Neuwelt, EA; Thompson, EM	1
Abajo, A; Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Ponz, M; Rodriguez, J; Zarate, R	1
Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M	1
Berglund, A; Byström, P; Einarsson, R; Glimelius, B; Johansson, B; Larsson, A; Nygren, P; Wernroth, L	1
Heinemann, V; Hoff, PM	1
Goubely, Y; Kirscher, S; Mineur, L; Molinari, N; Plat, F; Sabatier, R	1
Apolloni, C; Ditto, A; Frigerio, L; Melpignano, M; Panici, PB; Pignata, S; Raspagliesi, F; Scambia, G; Scollo, P; Selvaggi, L	1
Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K	1
Colucci, G; De Vita, F; Giuliani, F; Pisconti, S	1
Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S	1
Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ	1
Buzaid, AC; Esser, R; Fein, L; Hidalgo, J; Lerzo, G; Mathias, Cde C; Murad, AM; Perazzo, F; Senger, S; Simon, SD	1
Ashley, S; Charalambous, H; Chau, I; Cunningham, D; Hawkes, E; Koukouma, A; Okines, AF; Papamichael, D; Rao, S	1
Brown, MS; Cloughesy, T; Das, A; Goldin, J; Hambleton, J; Huo, J; Kim, HJ; Paton, VE; Pope, WB; Xia, Q	1
Chin, K; Esaki, T; Furukawa, H; Hamada, C; Iishi, H; Imamoto, H; Imamura, H; Narahara, H; Sakata, Y; Tsuburaya, A	1
Advani, S; Bonaventura, A; Cheirsilpa, A; Esser, R; Hsieh, RK; Im, SA; Lim, R; Mueser, M; Sun, Y; Yau, TK	1
Li, Y; Liu, J; Ren, Y	1
Bearzi, I; Biscotti, T; Cascinu, S; Falcone, A; Faloppi, L; Galizia, E; Giampieri, R; Labianca, R; Loupakis, F; Mandolesi, A; Scartozzi, M; Zaniboni, A; Zorzi, F	1
Coan, A; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ	1
Bubenzer, J; do O, N; Fuchs, R; Luedde, T; Roderburg, C; Spannbauer, M; Tischendorf, JJ; Trautwein, C	1
Barbato, E; Barberis, G; Comella, P; Condemi, G; Filippelli, G; Ionta, MT; Massidda, B; Natale, D; Palmeri, S; Putzu, C; Sandomenico, C; Tafuto, S; Vessia, G	1
Boc, M; Ocvirk, J; Rebersek, M	1
Hosomi, Y; Iguchi, M; Okamura, T; Okuma, Y; Shibuya, M; Takagi, Y	1
Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M	1
Altinbas, M; Camci, C; Dikilitas, M; Kalender, ME; Ozkan, M; Sevinc, A	1
Assenat, E; Bibeau, F; Bleuse, JP; Crapez-Lopez, E; Desseigne, F; Kramar, A; Mineur, L; Portales, F; Samalin, E; Thezenas, S; Viret, F; Ychou, M	1
Bechter, O; Dlaska, M; Eisterer, W; Fridrik, MA; Greil, R; Grünberger, B; Mayrbäurl, B; Obrist, P; Russ, G; Thaler, J; Wöll, E; Zabernigg, A	1
Assy, N; Basher, W; Chetver, L; Shnaider, J; Zidan, J	1
Delattre, JY; Gállego Pérez-Larraya, J; González-Aguilar, A; Guillevin, R; Hoang-Xuan, K; Houillier, C; Lahutte, M; Petrirena, G; Reyes-Botero, G; Sanson, M	1
Grunnet, K; Hansen, S; Holmberg, M; Lassen, U; Møller, S; Poulsen, HS; Schultz, H; Sorensen, M	1
Burris, HA; Eakle, JF; Greco, FA; Hainsworth, JD; Lubiner, ET; Quinn, R; Rubin, MS; Shipley, D; Spigel, DR; Thompson, DS	1
Adam, R; Barroso, E; Capussotti, L; Elias, D; Figueras, J; Gigot, JF; Gruenberger, T; Herrera, J; Ijzermans, JN; Isoniemi, H; Laurent, C; Letoublon, C; Lucidi, V; Mirza, DF; Nuzzo, G; Pardo, F; Popescu, I; Poston, G; Sousa, FC; Viganò, L	1
Andrés, R; Balañá, C; Benavides, M; de Las Peñas, R; Fernández-Chacón, C; Gallego, O; García-Velasco, A; Gil, MJ; Herrero, A; Martínez-García, M; Mesia, C; Pérez-Martin, X; Peréz-Segura, P; Quintanar, T; Reynés, G	1
Cakar, B; Karabulut, B; Karaca, B; Sezgin, C; Uslu, R; Varol, U	1
Adenis, A; Adler, G; Aparicio, J; Barcelo, JR; Canon, JL; Cassinello, J; Castanon, C; Cunningham, D; D'Hondt, L; Fonseca, E; Garcia Giron, C; Hawkins, R; Hossfeld, DK; Kerger, J; Lofts, F; Lopez-Vivanco, G; Misset, JL; Mousseau, M; Nicolson, M; Rixe, O; Rodriguez, R; Roy, A; Schalhorn, A; Schoffski, P; Sörbye, H	1
Argiris, A; Arun, P; Feldman, LE; Forastiere, AA; Gilbert, J; Haigentz, M; Jang, M; Lee, JW; Van Waes, C	1
Chang, H; Cho, BC; Kim, HR; Kim, JH; Kim, SH; Lee, CG; Yoon, SH	1
Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R	1
Fukuda, M; Hayashi, N; Ikeda, T; Izumikawa, K; Kinoshita, A; Kohno, S; Nakamura, Y; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K; Yamaguchi, H	1
Antonelli, G; Blandino, R; Calì, S; Ferraù, F; Malaponte, E; Panebianco, V; Vitale, FV	1
Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Uchino, R; Yamamoto, N; Yatomi, Y	1
Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N	1
Chen, DY; Zhao, WY	1
Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M	1
Akman, T; Aktas, B; Alacacioglu, A; Balakan, O; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Engin, H; Gunaydin, Y; Harputluoglu, H; Kaplan, MA; Karaca, H; Ozdemir, NY; Sevinc, A; Sonmez, OU; Tonyali, O; Tufan, G; Tugba Unek, I	1
Ajani, JA; Baker, J; Charnsangavej, C; Feig, BW; Ho, L; Mansfield, PF; Pisters, PW	1
Depisch, D; Fiebiger, W; Kornek, GV; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H	1
Atagi, S; Furuse, K; Hosoe, S; Kawaguchi, T; Kawahara, M; Naka, N; Ogawara, M; Okishio, K; Takemoto, Y; Tsuchiyama, T; Ueno, K	1
Antonellini, A; Elfring, GL; Gillenwater, HH; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Sandler, AB; Socinski, MA	1
Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P	1
Bennouna, J; Ducreux, M; Hua, A; Lepille, D; Marre, A; Méry-Mignard, D; Mignot, L; Rougier, P	1
Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F	1
Rothenberg, ML	2
Bourhis, JH; Damaj, G; Dreyfus, F; Fenaux, P; Feremans, W; Guerci, A; Ravoet, C; Ribrag, V; Suzan, F; Vantelon, JM	1
Agelaki, S; Androulakis, N; Aravantinos, G; Dimopoulos, MA; Foutzilas, G; Georgoulias, V; Giannakakis, T; Janninis, D; Kouroussis, C; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG	1
Fuchs, CS; Harker, G; Hecht, JR; Moore, MR; Rinaldi, D; Villa, L	1
Armand, JP; Boige, V; Fabbro, M; Faivre, S; Frenay, M; Germa, C; Raymond, E; Rixe, O; Rodier, JM; Sicard, E; Vassal, G; Vernillet, L	1
Ballesteros, P; Bohn, U; Cassinello, J; Dorta, J; Fernández, JL; Huidobro, G; Jorge, M; López, R; López-Alvarez, P; Martínez-Guisado, A; Pérez-Carrión, R; Sevilla, I; Valladares, M	1
Glimelius, B	1
Ansell, W; Nystrom, M; Oliver, RT; Shamash, J; Steele, JP; Wilson, P	1
Hinkelbein, W; Mühr-Wilkenshoff, F; Ohnesorge, I; Riecken, EO; Scherübl, H; Wolf, KJ; Zeitz, M	1
Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y	1
Haller, DG	1
Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM	1
Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J	1
Fujimoto, T; Hashimoto, M; Ishibashi, K; Iwasaki, K; Kato, H; Ogawa, K; Umehara, A; Yokomizo, H; Yoshida, K; Yoshimatsu, K	1
Chu, E	1
Bugat, R; Catane, R; Clemens, M; Di Betta, D; Ducreux, M; Fages, B; Figer, I; Gips, M; Jacques, C; Klein, B; Knuth, A; Köhne, CH; Niederle, N; Preusser, P; Shani, A; Thuss-Patience, P; Wilke, HJ	1
Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N	1
Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L	1
Kataoka, M; Kondo, K; Shimoyama, S	1
Bramis, J; Delladetsima, JK; Giannopoulos, A; Kouraklis, G; Polyzos, A; Sfikakis, PP	1
Bria, E; Garufi, C; Sperduti, I; Terzoli, E; Vanni, B; Zappalà, AM	1
Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH	1
Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H	1
Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G	1
Bafaloukos, D; Bamias, A; Economopulos, T; Fountzilas, G; Janinis, J; Kalofonos, HP; Kouvatseas, G; Papakostas, P; Skarlos, D; Stavropoulos, M; Timotheadou, E	1
Cohen, MH; Griebel, DJ; Hirschfeld, S; Ibrahim, A; Pazdur, R; Williams, GA	1
Kitakata, H; Mai, M; Minamoto, T; Omote, K; Takahashi, Y; Yamashita, K; Yasumoto, K	1
Cloughesy, T; Filka, E; Fruehauf, JP; Mehta, R; Parker, RJ	1
Barón, MG; Castañón, C; de Tejada, MR; Escudero, P; Feliu, J; López-Gómez, L; Martín, MS; Martínez, MP; Pericay, C; Rodríguez-García, JM; Salud, A; Sánchez, JJ	1
Chen, VM; Flower, RL; Jackson, D; Morel-Kopp, MC; Thrift, KM; Ward, CM	1
Agelidou, A; Ardavanis, A; Boukovinas, I; Georgoulias, V; Kouroussis, C; Palamidas, P; Polyzos, A; Stavrinidis, E; Syrigos, K; Toubis, M; Tselepatiotis, E; Veslemes, M; Vlachonikolis, I	1
Kishida, T; Komiyama, M; Mori, T; Noguchi, M; Noguchi, Y; Ohnishi, M; Sawaguchi, K; Yabushita, H	1
Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C	1
Bets, D; Bleiberg, H; Chau, I; Cunningham, D; Harstrick, A; Humblet, Y; Khayat, D; Mueser, M; Santoro, A; Siena, S; Van Cutsem, E; Verslype, C	1
Chau, I; Cunningham, D; Dickson, J; Hill, M; Lal, R; Middleton, G; Norman, AR; Oates, J; Ross, PJ; Topham, C	1
Cisar, LA; Green, MR; Gruia, G; Jeffrey, GM; Miller, LL; Miller, WH; Morganti, A; Orlando, N; Rocha Lima, CM; Rotche, R	1
Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E	1
Cantore, M; Del Freo, A; Fiorentini, G; Iacono, C; Mambrini, A; Manni, A; Oliani, C; Rabbi, C; Zamagni, D	1
Hayashi, N; Koshiishi, H; Koshiishi, Y; Okamura, T; Takahashi, E; Tamamoto, F; Yoshimura, T	1
Cheung, YB; Chowbay, B; Leong, SS; Poon, D; Tan, EH	1
Cortés-Funes, H; García-Velasco, A; Gonzalez, E; Gravalos, C; Quintela-Fandino, M	1
Paukstadt, W	1
Minsky, BD	1
Artandi, M; Borner, M; Boussard, B; Carlsson, G; Espana, P; Graeven, U; Ridwelski, K; Rosales, AM; Schmiegel, W; Schölmerich, J	1
Venook, A	1
Alexander, HR; Bartlett, DL; Beresneva, T; Helsabeck, C; Libutti, SK; Pingpank, JF	1
Hamanaka, N; Ikehara, M; Noda, K; Oshita, F; Saito, H; Yamada, K	1
Kosmas, Ch; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdaridis, D; Xynotroulas, J	1
Im, YH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, ST; Kim, WS; Lee, J; Lee, SH; Park, JO; Park, K; Park, KW; Park, YS	1
Green, MR; Herndon, JE; Kindler, HL; Zhang, C	1
Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ	1
Bang, SM; Cho, EK; Choi, EY; Chung, M; Ki Lee, W; Lee, JH; Park, SH; Shin, DB	1
Anak, O; Bokemeyer, C; El-Serafi, M; Frickhofen, N; Fuchs, R; Genicot, B; Köhne, CH; Langenbuch, T; Lorenz, M; Lutz, MP; Mergenthaler, HG; Müller, L; Nordlinger, B; Reichardt, P; Rougier, P; Rückle-Lanz, H; van Cutsem, E; Vanhoefer, U; Voigtmann, R; Wils, J	1
Braun-Falco, M; Holtmann, C; Lordick, F; Ring, J	1
Agelidou, A; Androulakis, N; Boukovinas, I; Chandrinos, V; Georgoulias, V; Ignatiadis, M; Kentepozidis, N; Mylonaki, E; Vossos, A; Zachariadis, E; Ziotopoulos, P	1
Barni, S; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Gasparini, G; Graziano, F; Labianca, R; Scartozzi, M; Sobrero, A; Zaniboni, A	1
Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G	1
Ahn, JS; Chang, HM; Kang, WK; Kang, YK; Kim, HK; Kim, SR; Kim, TW; Lee, KH; Park, JO; Ryoo, BY; Zang, DY	1
Almerud, A; Gubanski, M; Lideståhl, A; Lind, PA; Naucler, G	1
Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B	1
Han, JY; Kim, EA; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Park, CG; Yoon, SM	1
Chan, AT; Ho, WM; King, A; Koh, J; Lai, P; Leow, CK; Lim, R; Ma, B; Mok, T; Wong, YY; Yeo, W	1
Andersen, N; Brandt, D; Davies, MJ; Murren, JR; Nadkarni, R; Parisot, N; Pizzorno, G; Psyrri, D; Rose, M; Rosenfield, AT; Zelterman, D	1
Saltz, LB	1
Rosati, G	1
Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L	1
Hojo, M; Izumi, S; Kamimura, M; Kobayashi, K; Kudo, K; Naka, G; Takeda, Y; Tsuduki, E	1
Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS	1
Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T	1
Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N	1
Grothey, A; Kim, GP	1
Arcamone, G; Bertolini, P; Bisogno, G; Carli, M; Paolucci, P; Prete, A; Provenzi, M; Riccardi, R; Ruggiero, A; Surico, G	1
Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M	1
Chan, S; Clamp, AR; Cruickshank, D; Hindley, A; Jayson, GC; Ledermann, J; Mäenpää, J; Sorbe, B; Vasey, P; Welch, R; Wilkinson, PM	1
Boige, V; Debaere, T; Ducreux, M; Hannoun, L; Hebbar, M; Magherini, E; Malka, D; Mignard, D; Poynard, T; Taïeb, J	1
Fujita, J; Hoshimoto, S; Kato, R; Kato, T; Morise, Z; Sugioka, A	1
Buxhofer-Ausch, V; Hinterberger, W; Hinterberger-Fischer, M	1
Ichikawa, W; Inokuchi, M; Kawano, T; Kojima, K; Nihei, Z; Sugihara, K; Yamada, H; Yamashita, T	1
Abbruzzese, JL; Atkins, JN; Blanke, CD; Dakhil, SR; Gandara, DR; McCoy, SA; Paradelo, JC; Williamson, SK; Yost, KJ	1
André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A	1
Fukuda, M; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Takatani, H; Tsurutani, J	1
Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N	1
Büscher, C; Fähndrich, S; Fietkau, R; Klautke, G; Semrau, S; Virchow, C	1
Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M	1
In, KH; Jeong, HC; Kang, KH; Kim, JH; Lee, SY; Shim, JJ; Shin, C; Yoo, SH	1
Hasegawa, F; Komatsu, T; Nishio, K; Ochiya, T; Takeshita, F; Takigahira, M; Yanagihara, K	1
Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C	1
Bauer, J; Bouzourene, H; Coucke, P; Leyvraz, S; Matter, M; Stupp, R; Voelter, V; Vuilleumier, H; Zouhair, A	1
Han, MJ; Kang, WK; Kim, HJ; Kwon, JM; Lee, HR; Lee, J; Lim, HY; Oh, SY; Park, BB; Park, JO; Park, YS	1
Capanu, M; D'Adamo, D; Ilson, DH; Kelsen, DP; Levnor, A; O'Reilly, E; Ramanathan, RK; Schwartz, GK; Schwartz, L; Shah, MA; Trocola, R; Tse, A	1
Barone, C; Basso, M; Cassano, A; D'Argento, E; Di Leonardo, G; Landriscina, M; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N	1
Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Wilson, G	1
Falk, S; Glynne-Jones, R; Maughan, TS; Meadows, HM; Sebag-Montefiore, D	1
Assadourian, S; Bergeron, C; Cisar, L; Couanet, D; Gentet, JC; Geoerger, B; Geoffray, A; Morland, B; Orbach, D; Pichon, F; Picton, S; Stockdale, E; Vassal, G	1
Adena, M; Damianovich, D; Tebbutt, NC	1
Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ	1
Battistoni, F; Dicuonzo, G; Gavasci, M; Gebbia, N; Rocci, L; Rosaria, VM; Russo, A; Santini, D; Tonini, G; Vincenzi, B	1
El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM	1
Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Lee, SY; Yoon, SJ	1
Han, JY; Kim, HT; Lee, DH; Lee, JE; Lee, JS; Lee, SY; Lim, HS; Park, YH; Shin, ES; Yoo, YK	1
Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ	1
Abrahantes, JC; André, T; Burzykowski, T; Buyse, M; Carola, E; Cervantes, A; Chirivella, I; de Gramont, A; Etienne, PL; Figer, A; Flesch, M; Lledo, G; Louvet, C; Mineur, L; Perez-Staub, N; Quinaux, E; Rivera, F; Tabah-Fisch, I; Tournigand, C	1
Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT	1
Arena, MG; Di Lauro, L; Foggi, P; Lopez, M; Nunziata, C; Sperduti, I	1
Briasoulis, E; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Pectasides, D; Samantas, E; Skarlos, D; Syrigos, K	1
Bearzi, I; Berardi, R; Biscotti, T; Cascinu, S; Catalano, V; Falcone, A; Labianca, R; Loupakis, F; Mandolesi, A; Pierantoni, C; Quadri, A; Scartozzi, M; Zaniboni, A; Zorzi, F	1
Burris, HA; Grapski, R; Greco, FA; Hainsworth, JD; Mallidi, PV; Meng, C; Schreeder, M; Simons, L; Spigel, DR; Yardley, DA	1
Chen, HX; Gonen, M; Hochster, HS; Hoff, PM; Hollywood, EM; Kemeny, NE; Kindler, HL; Lenz, HJ; Morse, M; Quinones, M; Saltz, LB; Wadler, S	1
Abad, A; Alonso, V; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Manzano, JL; Marcuello, E; Martinez-Villacampa, M; Massuti, B; Rivera, F; Tabernero, J; Vega, ME; Yuste, AL	1
Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A	1
Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY	1
Hanyu, F; Harada, N; Hayashi, T; Suzuki, M; Suzuki, S; Takeo, Y; Tanaka, S	1
Cho, EK; Chung, M; Lee, JH; Lee, SI; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB	1
Aegerter, P; Afchain, P; André, T; Bachet, JB; Bouchahda, M; Fermanian, C; Landi, B; Levi, F; Lièvre, A; Louvet, C; Mitry, E; Rougier, P	1
Charoentum, C; Chewasakulyong, B; Euathrongchit, J; Munprakan, S; Sorraritchingchai, S; Thongprasert, S	1
Goldberg, RM; Grothey, A; Hedrick, EE; Hurwitz, HI; Mass, RD; Ramanathan, RK; Sargent, DJ; Sarkar, S; Suzuki, S	1
Endlicher, E; Golder, S; Grossmann, J; Herfarth, H; Herold, T; Kullmann, A; Kullmann, F; Schlottmann, K; Troppmann, M	1
Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Siriwittayakorn, P; Somwangprasert, A; Sukthomya, V; Tharavichitkul, E	1
Hamaguchi, T; Kajiwara, T; Kato, K; Matsubara, J; Moriwaki, T; Nakajima, TE; Nishina, T; Oka, T; Okayama, Y; Shimada, Y; Shimoda, T; Shirao, K; Yamada, Y	1
An, CH; Cho, EK; Choi, SJ; Jeong, SH; Kim, Y; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB	1
Tang, X; Wang, G; Wang, Z; Wu, H; Wu, Z; Zhu, D	1
Chamberlain, MC	2
Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Lee, SS; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH	1
Cordoba-Rodriguez, R; Fuchs, C; Giusti, RM; Hughes, M; Keegan, P; Koti, K; Men, AY; Pazdur, R; Pilaro, AM; Rothmann, M; Shastri, K; Weiss, KD; Zhao, H	1
Carcereny, E; Casado, E; Fernández-Llamazares, J; Font, A; Gallego, R; Guix, M; Manzano, JL; Maurel, J; Ramirez, JL; Rosell, R; Salazar, R; Tabernero, J; Taron, M	1
Altes, A; Baiget, M; Culverhouse, R; Hoskins, JM; Marcuello, E; Marsh, S; Maxwell, T; McLeod, HL; Paré, L; Van Booven, DJ	1
Andreoni, F; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Floriani, I; Fontana, A; Giustini, L; Graziano, F; Humar, B; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Rulli, E; Ruzzo, A; Santini, D; Schiavon, G; Tonini, G; Torresi, U	1
Bonnet, S; Boulet, T; Di Pietrantonio, D; Elias, D; Goere, D; Honore, C; Kohneh-Shahri, N; Raynard, B	1
Elinzano, H; Jin, T; Kang, TY; Peereboom, D	1
Agarwal, M; Beer, TM; Crawford, ED; Goldman, B; Nichols, CR; Petrylak, DP; Ryan, CW	1
Burris, HA; Eckardt, JR; Eckhardt, SG; Elfring, GL; Hilsenbeck, SG; Kuhn, JG; Nelson, J; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Smith, LS; Thurman, AM; Von Hoff, DD; Weiss, GR	1
Adenis, A; Becouarn, Y; Bonneterre, J; Brunet, P; Bugat, R; Burki, F; Conroy, T; Culine, S; Douillard, JY; Extra, JM; Ganem, G; Herait, P; Mahjoubi, M; Marty, M; Merrouche, Y; Mousseau, M; Namer, M; Negrier, S; Rougier, P; Seitz, JF; Suc, E; Ychou, M	1
Courtney, A; Cox, J; Meyer, W; Mues, G; Nemunaitis, J	1
Blessing, JA; Chafe, W; Kohler, M; Levenback, C; Look, KY; Roman, LD	1
Cox, JV; DeVore, RF; Elfring, GL; Geyer, CE; Hainsworth, JD; Macdonald, JS; Miller, LL; Mohrland, JS; Pazdur, R; Rivkin, SE; Rothenberg, ML; Sandbach, J; Von Hoff, DD; Wolf, DL	1
Ashley, D; Bigner, DD; Cloughsey, T; Cokgor, I; Colvin, OM; Elfring, GL; Friedman, AH; Friedman, HS; Haglund, M; Houghton, PJ; Kerby, T; Lawyer, J; Lovell, S; Malczyn, J; McLendon, RE; Miller, LL; Parry, M; Petros, WP; Provenzale, JM; Rasheed, K; Rich, J; Schaaf, LJ; Stewart, ES	1
Miller, M	1
Balatoni, G; Farczádi, E; Izsó, J; Kofi, AP; Kristó, K; Lohinszky, J; Pintér, T; Szántó, J	1
Hill, M; Price, T	1
Carbone, DP; Cohen, AG; Devore, RF; Jagasia, MH; Johnson, DH; Langer, CJ; Rodgers, JS; Schlabach, LL; Shyr, Y; Yunus, F	1
Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H	1
Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H	1
Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M	1
Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J	1
Aiba, K; Fujiwara, K; Horikoshi, N; Ito, Y; Mizunuma, N; Omachi, K; Saotome, T; Sugiyama, K; Takahashi, S	1
Bruckner, H; Compton, LD; Dudek, A; Eckardt, J; Elfring, GL; Green, MR; Hainsworth, J; Lester, E; Locker, PK; Miller, LL; Miller, W; Rocha Lima, CM; Savarese, D; Saville, W; Yunus, F	1
Hacker, U; Heinemann, V; Schalhorn, A; Stemmler, J; Weise, A	1
Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V	1
Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Crucitta, E; De Lucia, L; De Vita, F; Del Prete, S; Lorusso, V; Orditura, M; Palmeri, S	1

Reviews

19 review(s) available for irinotecan and Disease Exacerbation

Article	Year
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Withholding Treatment	2020
Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. Journal of vascular and interventional radiology : JVIR, 2013, Volume: 24, Issue:8 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Carriers; Humans; Irinotecan; Liver Neoplasms; Quality of Life; Survival Analysis; Time Factors; Treatment Outcome	2013
The effect of the UGT1A128 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. The pharmacogenomics journal, 2014, Volume: 14, Issue:5* Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Survival Analysis	2014
Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. International journal of colorectal disease, 2015, Volume: 30, Issue:10 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin	2015
The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer. Expert review of anticancer therapy, 2016, Volume: 16, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Humans; Irinotecan; Neoplasm Metastasis; Ramucirumab; Survival Rate; Treatment Outcome	2016
Evolving treatment of advanced colon cancer. Annual review of medicine, 2009, Volume: 60 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin	2009
Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer. Oncology research, 2010, Volume: 18, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Spheroids, Cellular; Survival Rate; Treatment Outcome	2010
[Metastatic gastric cancer: does second-line chemotherapy make sense?]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:38 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Irinotecan; Neoplasm Staging; Palliative Care; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Retreatment; Stomach Neoplasms; Survival Rate; Taxoids	2010
Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Approval; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Mutation; Organoplatinum Compounds; United States; United States Food and Drug Administration	2010
Maintenance therapy in colon cancer. Cancer treatment reviews, 2010, Volume: 36 Suppl 3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Disease Progression; Disease-Free Survival; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Rate	2010
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme]. Magyar onkologia, 2012, Volume: 56, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Disease Progression; Drug Approval; Europe; Glioblastoma; Humans; Hungary; Irinotecan; Magnetic Resonance Imaging; Off-Label Use; Recurrence; Temozolomide; Treatment Outcome	2012
Current status of capecitabine in the treatment of colorectal cancer. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Risk Factors; Stomatitis; Survival; Treatment Outcome	2002
Palliative treatment of patients with colorectal cancer. Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society, 2003, Volume: 92, Issue:1 Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Palliative Care; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Treatment Outcome; Uracil	2003
Chemotherapy for advanced pancreatic cancer. International journal of radiation oncology, biology, physics, 2003, Volume: 56, Issue:4 Suppl Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Random Allocation; Treatment Outcome	2003
[5-fluorouracil and leucovorin therapy for advanced colorectal cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; United States	2003
Current status of second-line therapy for metastatic colorectal cancer. Clinical colorectal cancer, 2004, Volume: 4 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Therapy, Combination; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Salvage Therapy	2004
Combined-modality therapy of rectal cancer with irinotecan-based regimens. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome	2004
Critical evaluation of current treatments in metastatic colorectal cancer. The oncologist, 2005, Volume: 10, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Medical Oncology; Neoplasm Metastasis; Vascular Endothelial Growth Factors	2005
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway. Clinical colorectal cancer, 2005, Volume: 5 Suppl 2 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome	2005

Trials

195 trial(s) available for irinotecan and Disease Exacerbation

Article	Year
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 01-20, Volume: 40, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Progression-Free Survival; Time Factors	2022
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-01, Volume: 40, Issue:4 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Functional Status; Humans; Immune Checkpoint Inhibitors; Irinotecan; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome	2022
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC). BMC cancer, 2023, May-22, Volume: 23, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Frontotemporal Dementia; Gemcitabine; Humans; Irinotecan; Prospective Studies; Trifluridine	2023
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study. Thoracic cancer, 2023, Volume: 14, Issue:28 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma	2023
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA network open, 2023, 09-05, Volume: 6, Issue:9 Topics: Aged; Cetuximab; Colonic Neoplasms; Disease Progression; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Rectal Neoplasms	2023
Encorafenib, Binimetinib, and Cetuximab in The New England journal of medicine, 2019, 10-24, Volume: 381, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Disease Progression; Electrocorticography; Female; Humans; Intention to Treat Analysis; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Analysis	2019
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. Trials, 2019, Dec-19, Volume: 20, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotyping Techniques; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Phenylurea Compounds; Precision Medicine; Prodrugs; Progression-Free Survival; Pyridines; Randomized Controlled Trials as Topic; Time Factors; Young Adult	2019
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020, Volume: 52, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progression; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; France; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate	2020
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR European journal of cancer (Oxford, England : 1990), 2020, Volume: 136 Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome	2020
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). European journal of cancer (Oxford, England : 1990), 2021, Volume: 147 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Disease Progression; Female; Germany; Humans; Irinotecan; Male; Neoplasm Metastasis; Progression-Free Survival; Sex Factors; Time Factors; Topoisomerase I Inhibitors	2021
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. British journal of cancer, 2017, May-09, Volume: 116, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Quality of Life; Retreatment; Survival Rate	2017
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Oct-10, Volume: 35, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome	2017
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3. Anticancer research, 2017, Volume: 37, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Bevacizumab; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Time Factors; Treatment Outcome	2017
Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer. Clinical colorectal cancer, 2018, Volume: 17, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Oxaliplatin; Palliative Care; Panitumumab; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Tumor Burden; Young Adult	2018
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis. Pathology oncology research : POR, 2019, Volume: 25, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Ki-67 Antigen; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53	2019
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. JAMA oncology, 2019, 01-01, Volume: 5, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins p21(ras); Time Factors	2019
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. European journal of cancer (Oxford, England : 1990), 2019, Volume: 106 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Reported Outcome Measures; Progression-Free Survival; Quality of Life; Time Factors	2019
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA oncology, 2019, 03-01, Volume: 5, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, ras; Humans; Irinotecan; Italy; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins B-raf; Risk Factors; Time Factors	2019
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC cancer, 2018, Dec-29, Volume: 18, Issue:1 Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult	2018
A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer. Oncology, 2019, Volume: 97, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease Progression; Febrile Neutropenia; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Rectal Neoplasms	2019
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sirolimus; Treatment Outcome	2013
Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703. Respiratory investigation, 2013, Volume: 51, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Endpoint Determination; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Salvage Therapy; Survival Rate; Treatment Outcome	2013
Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI(®)) for colorectal liver metastases does not predict tumour destruction or long-term outcome. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2013, Volume: 39, Issue:10 Topics: Adult; Aged; Angiography; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Contrast Media; Disease Progression; Drug Delivery Systems; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome	2013
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. British journal of cancer, 2014, Mar-04, Volume: 110, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib	2014
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Investigational new drugs, 2014, Volume: 32, Issue:4 Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Membrane Glycoproteins; Middle Aged; Young Adult	2014
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins	2015
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome	2015
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome	2015
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Failure	2015
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Febrile Neutropenia; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Salvage Therapy; Sulfonamides; Treatment Outcome	2015
Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Jan-10, Volume: 34, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Patient Selection; Radiotherapy, Adjuvant; Rhabdomyosarcoma; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome; Vincristine	2016
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Apr-20, Volume: 34, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infant; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Tablets; Temozolomide; Time Factors; Treatment Outcome; United States; Young Adult	2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Time Factors; Treatment Failure	2016
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. British journal of cancer, 2016, Aug-09, Volume: 115, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin	2016
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:12 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Ramucirumab	2016
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget, 2016, Dec-13, Volume: 7, Issue:50 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2016
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin	2008
A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities. Clinical colorectal cancer, 2008, Volume: 7, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Time Factors; Treatment Outcome	2008
A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. Journal of neuro-oncology, 2008, Volume: 90, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Immunosuppressive Agents; Irinotecan; Male; Middle Aged; Survival Analysis; Thalidomide	2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:5 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome; Young Adult	2009
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Rectal Neoplasms; Remission Induction; Survival Rate; Vomiting; Young Adult	2008
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. The oncologist, 2008, Volume: 13, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Prospective Studies; Quality of Life; Treatment Outcome	2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-01, Volume: 26, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pain Measurement; Survival Analysis; Treatment Outcome	2008
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Time Factors; Treatment Outcome	2009
A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Tegafur	2009
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies	2009
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. Clinical colorectal cancer, 2008, Volume: 7, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Statistics, Nonparametric; Treatment Outcome	2008
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome	2009
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer investigation, 2009, Volume: 27, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Digestive System Neoplasms; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Time Factors; Treatment Outcome	2009
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:5 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Survival Analysis	2009
A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors. Anti-cancer drugs, 2009, Volume: 20, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Taxoids; Treatment Outcome	2009
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC cancer, 2009, Apr-14, Volume: 9 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Vomiting	2009
Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome	2009
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival Analysis; Treatment Outcome	2010
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer]. Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Salvage Therapy; Survival Rate; Vomiting; Young Adult	2009
Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics, 2010, Jun-01, Volume: 77, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Camptothecin; Disease Progression; Drug Administration Schedule; Feasibility Studies; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Survival Analysis	2010
Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer. Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Treatment Outcome	2011
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Apr-01, Volume: 16, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyridazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult	2010
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer. Investigational new drugs, 2011, Volume: 29, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Decision Making; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Research Personnel; Survival Analysis; Tegafur; Time Factors; Treatment Outcome	2011
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. Clinical lung cancer, 2010, Jul-01, Volume: 11, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome	2010
Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Doxorubicin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Small Cell Lung Carcinoma; Treatment Outcome	2011
Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Recurrence; Rhabdomyosarcoma; Risk Factors; Time Factors; Treatment Outcome; United States; Vincristine	2010
An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer. Oncology reports, 2010, Volume: 24, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Blood Chemical Analysis; Camptothecin; Disease Progression; Docetaxel; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Predictive Value of Tests; Prognosis; Taxoids; Upper Gastrointestinal Tract	2010
A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms	2010
Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. Onkologie, 2010, Volume: 33, Issue:12 Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prospective Studies; Survival Rate; Treatment Outcome; Tumor Burden	2010
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tegafur; Treatment Failure	2012
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cinnamates; Colorectal Neoplasms; Cyclohexanes; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epoxy Compounds; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Models, Statistical; Oxaloacetates; Republic of Korea; Sesquiterpenes; Survival Analysis; Treatment Failure	2012
Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study. Clinical colorectal cancer, 2010, Volume: 9, Issue:5 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Survival Rate; Treatment Outcome	2010
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology, 2011, Feb-01, Volume: 76, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local	2011
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2011, Volume: 14, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult	2011
Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study. World journal of gastroenterology, 2011, Apr-14, Volume: 17, Issue:14 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Humans; Irinotecan; Neoplasm Metastasis; Survival Rate; Treatment Outcome	2011
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer, 2011, Dec-01, Volume: 117, Issue:23 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local	2011
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. The oncologist, 2011, Volume: 16, Issue:11 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate	2011
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT). Anticancer research, 2011, Volume: 31, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome	2011
First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study. Journal of clinical gastroenterology, 2012, Volume: 46, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult	2012
A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Standard of Care; Survival Rate; Young Adult	2012
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2012, Volume: 77, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Indoles; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome	2012
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. British journal of cancer, 2012, Jul-24, Volume: 107, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Taxoids	2012
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of Head & neck, 2013, Volume: 35, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Squamous Cell; Cytokines; Disease Progression; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; NF-kappa B; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2013
Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer. Anticancer research, 2012, Volume: 32, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging	2012
Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome	2012
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Polymorphism, Genetic; Prospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome	2013
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report Pathologie-biologie, 2013, Volume: 61, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Colorectal Neoplasms; Disease Progression; Drug Chronotherapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome	2013
[A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Thrombocytopenia	2012
Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:5 Suppl 5 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Survival Rate	2002
Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2002, Volume: 37, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival; Thrombocytopenia	2002
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma. Cancer, 2002, Oct-01, Volume: 95, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Vomiting	2002
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival; Treatment Outcome	2002
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. Anti-cancer drugs, 2002, Volume: 13, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Failure	2002
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts. Leukemia, 2003, Volume: 17, Issue:2 Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Blast Crisis; Bone Marrow; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Time Factors	2003
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:3 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome	2003
Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-01, Volume: 21, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Prospective Studies; Quality of Life; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome	2003
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Treatment Outcome; Vomiting	2003
Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer. Medical oncology (Northwood, London, England), 2003, Volume: 20, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome	2003
IPM chemotherapy in cytokine refractory renal cell cancer. British journal of cancer, 2003, May-19, Volume: 88, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Kidney Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Survival; Treatment Outcome	2003
A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. International journal of colorectal disease, 2003, Volume: 18, Issue:4 Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Survival Analysis	2003
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin	2003
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:7 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome	2003
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome	2003
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. British journal of cancer, 2003, Sep-15, Volume: 89, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Progression; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2003
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:6 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Rectal Neoplasms; Topoisomerase I Inhibitors	2003
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. British journal of cancer, 2003, Oct-20, Volume: 89, Issue:8 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome	2003
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. British journal of cancer, 2003, Nov-17, Volume: 89, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome	2003
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-01, Volume: 9, Issue:16 Pt 1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome	2003
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. British journal of cancer, 2004, Jan-26, Volume: 90, Issue:2 Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Tegafur; Treatment Outcome; Uracil	2004
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma. Cancer investigation, 2003, Volume: 21, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis	2003
FDA drug approval summaries: oxaliplatin. The oncologist, 2004, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Approval; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Random Allocation; Recurrence; United States; United States Food and Drug Administration	2004
Pilot study of low-dose, divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer. Surgery today, 2004, Volume: 34, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Stomach Neoplasms	2004
A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. Journal of neuro-oncology, 2004, Volume: 66, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome	2004
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. British journal of cancer, 2004, Apr-19, Volume: 90, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome	2004
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. British journal of cancer, 2004, Aug-02, Volume: 91, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids	2004
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC cancer, 2004, Jul-20, Volume: 4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Remission Induction; Treatment Outcome	2004
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England journal of medicine, 2004, Jul-22, Volume: 351, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Exanthema; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Single-Blind Method; Survival Analysis; Topoisomerase I Inhibitors	2004
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Aug-01, Volume: 22, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Prospective Studies; Thymidylate Synthase	2004
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Sep-15, Volume: 22, Issue:18 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis	2004
Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. Medical oncology (Northwood, London, England), 2004, Volume: 21, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neutropenia; Prospective Studies; Safety; Time Factors	2004
Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology, 2004, Volume: 67, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2004
Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer, 2005, Feb-01, Volume: 103, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutropenia; Quality of Life; Salvage Therapy; Survival Analysis; Treatment Outcome	2005
Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer. Oncology reports, 2005, Volume: 13, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Time Factors; Treatment Outcome	2005
Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer. Journal of experimental therapeutics & oncology, 2004, Volume: 4, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Organoplatinum Compounds; Time Factors; Treatment Outcome	2004
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:5 Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Taxoids	2005
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. British journal of cancer, 2005, May-23, Volume: 92, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2005
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Progression; Female; Heart Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Survival Analysis; Treatment Outcome	2005
Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clinical colorectal cancer, 2005, Volume: 5, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis	2005
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anti-cancer drugs, 2005, Volume: 16, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Remission Induction; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome	2005
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome	2005
Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 50, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome	2005
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. American journal of clinical oncology, 2005, Volume: 28, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting	2005
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial. Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Prodrugs; Rectal Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome	2005
A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer. Medical oncology (Northwood, London, England), 2005, Volume: 22, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis	2005
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Medical oncology (Northwood, London, England), 2005, Volume: 22, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Survival Analysis	2005
Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer. Cancer biology & therapy, 2005, Volume: 4, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Time Factors	2005
Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer? Nature clinical practice. Oncology, 2005, Volume: 2, Issue:1 Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Humans; Irinotecan; Neoplasm Metastasis; Survival Analysis; Treatment Outcome	2005
Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer? Nature clinical practice. Gastroenterology & hepatology, 2005, Volume: 2, Issue:1 Topics: Adenocarcinoma; Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; DNA Topoisomerases, Type I; Drug Therapy, Combination; Follow-Up Studies; Humans; Irinotecan; Treatment Outcome	2005
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. Oncology, 2005, Volume: 69, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vomiting	2005
A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. British journal of cancer, 2005, Dec-12, Volume: 93, Issue:12 Topics: Administration, Oral; Adult; Aged; Antacids; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cholagogues and Choleretics; Cisplatin; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Maximum Tolerated Dose; Middle Aged; Sodium Bicarbonate; Survival Analysis; Ursodeoxycholic Acid	2005
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis	2006
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology, 2005, Volume: 69, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Time Factors; Treatment Outcome	2005
Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer, 2006, Feb-01, Volume: 106, Issue:3 Topics: Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Disease Progression; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neutropenia; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome	2006
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Annals of surgical oncology, 2006, Volume: 13, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome	2006
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. British journal of cancer, 2006, Jan-16, Volume: 94, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2006
Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers; Camptothecin; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Liver Cirrhosis; Liver Neoplasms; Male	2006
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. British journal of cancer, 2006, Apr-24, Volume: 94, Issue:8 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Safety; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome	2006
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. American journal of clinical oncology, 2006, Volume: 29, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome	2006
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. British journal of cancer, 2006, May-08, Volume: 94, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome	2006
Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. British journal of cancer, 2006, May-08, Volume: 94, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome	2006
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. Oncology, 2006, Volume: 70, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome	2006
Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Disease Progression; Dose Fractionation, Radiation; Esophagitis; Feasibility Studies; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pneumonia; Radiotherapy, Adjuvant; Remission Induction; Thrombocytopenia; Treatment Outcome	2006
Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Radiotherapy; Recurrence; Time Factors; Treatment Outcome	2006
Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Anti-cancer drugs, 2006, Volume: 17, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin	2006
CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II. British journal of cancer, 2006, Sep-18, Volume: 95, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Rectal Neoplasms; Recurrence; Treatment Outcome	2006
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome	2007
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-20, Volume: 24, Issue:33 Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A	2006
Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. British journal of cancer, 2007, Jan-15, Volume: 96, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Proliferation; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Feasibility Studies; Female; Fluorouracil; HT29 Cells; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Treatment Outcome	2007
Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. British journal of cancer, 2007, Jan-15, Volume: 96, Issue:1 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Treatment Outcome; Uracil	2007
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. British journal of cancer, 2007, Feb-26, Volume: 96, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pelvic Neoplasms; Rectal Neoplasms; Sensitivity and Specificity; Survival Rate; Treatment Outcome	2007
Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-01, Volume: 25, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Disease Progression; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Rhabdomyosarcoma; Survival Analysis; Treatment Outcome	2007
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome	2008
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics, 2007, Volume: 8, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A	2007
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Failure	2008
A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate	2008
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer, 2007, Jul-01, Volume: 110, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Gene Frequency; Genotype; Haplotypes; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neutropenia; Polymorphism, Genetic; Treatment Outcome	2007
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:3 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome	2007
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome	2007
A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. Anti-cancer drugs, 2007, Volume: 18, Issue:8 Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Floxuridine; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Rate	2007
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. British journal of cancer, 2007, Sep-03, Volume: 97, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease Progression; Docetaxel; Esophagogastric Junction; Female; Fever; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting	2007
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 58, Issue:3 Topics: Adult; Aged; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate	2007
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:9 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Virginia	2007
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-10, Volume: 25, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome	2007
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome	2008
FOLFIRI chemotherapy for metastatic colorectal cancer patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival; Time Factors; Treatment Outcome	2007
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World journal of gastroenterology, 2007, Dec-14, Volume: 13, Issue:46 Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Thrombospondins; Vascular Endothelial Growth Factor A	2007
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome	2008
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Irinotecan; Male; Middle Aged; Taxoids; Treatment Outcome	2007
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study. Oncology, 2007, Volume: 72, Issue:5-6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis	2007
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Topotecan	2008
A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Disease Progression; Docetaxel; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Remission Induction; Stomach Neoplasms; Survival Analysis; Taxoids	2008
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-01, Volume: 14, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Approval; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Rate; United States; United States Food and Drug Administration	2008
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease Progression; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Single Nucleotide; Stomach Neoplasms; Survival Analysis; Taxoids; Xeroderma Pigmentosum Group D Protein	2008
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy. Clinical genitourinary cancer, 2008, Volume: 6, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome; Urologic Neoplasms	2008
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:4 Topics: Adenocarcinoma; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Irinotecan; Loperamide; Salvage Therapy; Survival Analysis; Treatment Outcome	1996
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction	1997
A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecologic oncology, 1998, Volume: 70, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Treatment Outcome; Uterine Cervical Neoplasms	1998
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer, 1999, Feb-15, Volume: 85, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Vomiting	1999
Irinotecan therapy in adults with recurrent or progressive malignant glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma	1999
UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:10 Suppl 9 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Tegafur; Treatment Outcome; Uracil	2000
Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome	2001
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome	2001
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin	2001
Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:18 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Tegafur; Uracil	2001
Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. Cancer investigation, 2002, Volume: 20, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Treatment Outcome	2002
Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience. Cancer, 2002, Feb-01, Volume: 94, Issue:3 Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Analysis; Thrombocytopenia; Treatment Outcome	2002
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-01, Volume: 20, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Radiography; Safety; Survival Rate; Treatment Outcome	2002
Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology, 2002, Volume: 56, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Salvage Therapy; Supratentorial Neoplasms; Thrombocytopenia	2002
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. British journal of cancer, 2002, Jun-17, Volume: 86, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome	2002

Other Studies

147 other study(ies) available for irinotecan and Disease Exacerbation

Article	Year
Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. International journal of molecular sciences, 2021, Oct-09, Volume: 22, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Male; MicroRNAs; Middle Aged; Multivariate Analysis; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies	2021
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. BMC cancer, 2021, Oct-29, Volume: 21, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Progression-Free Survival; Pyrimidines; Retrospective Studies; Time Factors	2021
Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02). Medicine, 2021, Dec-23, Volume: 100, Issue:51 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Disease Progression; Female; Humans; Indoles; Irinotecan; Male; Neuroectodermal Tumors, Primitive, Peripheral; Prospective Studies; Quality of Life; Quinolines; Sarcoma, Ewing; Treatment Outcome; Vincristine; Young Adult	2021
Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. European journal of cancer (Oxford, England : 1990), 2022, Volume: 172 Topics: Disease Progression; Humans; Hypoalbuminemia; Immune Checkpoint Inhibitors; Irinotecan; Programmed Cell Death 1 Receptor; Stomach Neoplasms	2022
Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes. Acta biomaterialia, 2019, Volume: 99 Topics: Animals; Antineoplastic Agents; Autophagy; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Disease Progression; Female; Fibrosis; Humans; Hydroxychloroquine; Irinotecan; Liposomes; Mice; Mice, Nude; Nanomedicine; Neoplasm Metastasis; Neoplasm Transplantation; NIH 3T3 Cells; Paclitaxel; Pancreatic Neoplasms; Peptides; Wound Healing	2019
Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. Cancer research, 2020, 02-01, Volume: 80, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Evolution; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Models, Theoretical; Multicenter Studies as Topic; Panitumumab; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate	2020
Orally Deliverable Nanotherapeutics for the Synergistic Treatment of Colitis-Associated Colorectal Cancer. Theranostics, 2019, Volume: 9, Issue:24 Topics: Administration, Oral; Animals; Apoptosis; Azoxymethane; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colitis; Colorectal Neoplasms; Curcumin; Cytokines; Dextran Sulfate; Disease Models, Animal; Disease Progression; Drug Synergism; Female; Inflammation; Inflammation Mediators; Intestines; Irinotecan; Macrophages; Mice; Mice, Inbred C57BL; Nanoparticles; RAW 264.7 Cells	2019
The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy. Cancer medicine, 2020, Volume: 9, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Prospective Studies; Transforming Growth Factor beta	2020
Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom. European journal of cancer care, 2020, Volume: 29, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Analgesics, Opioid; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease Progression; Docetaxel; Emergency Service, Hospital; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; France; Germany; Guideline Adherence; Hospice Care; Hospitalization; Humans; Irinotecan; Male; Middle Aged; Nutritional Support; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Receptor, ErbB-2; Retrospective Studies; Spain; Stomach Neoplasms; Treatment Failure; United Kingdom	2020
Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Diarrhea; Disease Progression; Drug Administration Schedule; Humans; Irinotecan; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Salvage Therapy; Sarcoma, Ewing; Temozolomide	2021
Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate	2021
Combination of Bronchial Arterial Infusion Chemotherapy plus Drug-Eluting Embolic Transarterial Chemoembolization for Treatment of Advanced Lung Cancer-A Retrospective Analysis of 23 Patients. Journal of vascular and interventional radiology : JVIR, 2020, Volume: 31, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Chemoembolization, Therapeutic; Disease Progression; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Treatment Outcome	2020
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china. Expert review of pharmacoeconomics & outcomes research, 2021, Volume: 21, Issue:4 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Rate	2021
The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients. Medical hypotheses, 2020, Volume: 144 Topics: Comorbidity; COVID-19; COVID-19 Drug Treatment; Critical Illness; Disease Outbreaks; Disease Progression; Drug Discovery; Drug Therapy, Combination; Etoposide; Humans; Irinotecan; SARS-CoV-2; Sepsis; Signal Transduction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Treatment Outcome; Virus Internalization; Virus Replication	2020
Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens. Pancreas, 2021, 01-01, Volume: 50, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Child; Disease Progression; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Pancreatic Neoplasms; Platinum Compounds; Progression-Free Survival; Retrospective Studies; Time Factors; Young Adult	2021
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. British journal of cancer, 2021, Volume: 124, Issue:12 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome	2021
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Lymphocytes; Male; Middle Aged; Neutrophils; Oxaliplatin; Oxaloacetates; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time Factors	2021
Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. European journal of cancer (Oxford, England : 1990), 2017, Volume: 78 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Cetuximab; Colonic Neoplasms; Disease Progression; Disease-Free Survival; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Panitumumab; Postoperative Care; Preoperative Care; Prospective Studies; Rectal Neoplasms; Registries	2017
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Annals of surgical oncology, 2017, Volume: 24, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Electrochemotherapy; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate	2017
Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. Journal of gastrointestinal cancer, 2018, Volume: 49, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Retreatment; Retrospective Studies; Treatment Outcome	2018
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2018, Volume: 22, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Male; Mesenteric Artery, Superior; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Second Primary; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Radiosurgery; Radiotherapy, Intensity-Modulated; Survival Rate	2018
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? Annals of surgical oncology, 2018, Volume: 25, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Contraindications, Procedure; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Oxaliplatin; Response Evaluation Criteria in Solid Tumors; Risk Factors; Survival Rate; Tomography, X-Ray Computed; Tumor Burden	2018
Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience. Clinical colorectal cancer, 2018, Volume: 17, Issue:3 Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies	2018
Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review. Medicine, 2018, Volume: 97, Issue:15 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Brain Neoplasms; Camptothecin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Oxonic Acid; Pyridines; Tegafur; Triple Negative Breast Neoplasms	2018
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. PharmacoEconomics, 2018, Volume: 36, Issue:11 Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom	2018
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Electronic Health Records; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Quality of Life; Retrospective Studies	2019
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. Journal of geriatric oncology, 2019, Volume: 10, Issue:4 Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure	2019
The clinical conundrum of managing relapsed small cell lung cancer. Cancer, 2019, 04-01, Volume: 125, Issue:7 Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan	2019
Synergy between dihydromyricetin intervention and irinotecan chemotherapy delays the progression of colon cancer in mouse models. Food & function, 2019, Apr-17, Volume: 10, Issue:4 Topics: Animals; Chloride Channels; Colonic Neoplasms; Disease Models, Animal; Disease Progression; Drug Synergism; Flavonols; Humans; Irinotecan; Male; Mice; Mice, Inbred C57BL; Mitochondrial Proteins	2019
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PloS one, 2019, Volume: 14, Issue:4 Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Clinical Decision-Making; Computer Simulation; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Models, Biological; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Remission Induction; Tumor Burden	2019
Comparison of Response and Outcomes of Drug-eluting Bead Chemoembolization (DEB-TACE) Anticancer research, 2019, Volume: 39, Issue:6 Topics: Aged; Antineoplastic Agents; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease Progression; Doxorubicin; Drug Carriers; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Time Factors	2019
Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Journal of hepato-biliary-pancreatic sciences, 2019, Volume: 26, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate	2019
Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Scientific reports, 2019, 07-31, Volume: 9, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Tumor Microenvironment	2019
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic	2013
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2013, Volume: 29, Issue:7 Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult	2013
Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged	2013
FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Oncology, 2013, Volume: 85, Issue:3 Topics: Adult; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Germany; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome	2013
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PloS one, 2013, Volume: 8, Issue:9 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease Progression; Endothelial Cells; Female; Glioblastoma; GPI-Linked Proteins; Humans; Immunophenotyping; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Prognosis; Treatment Outcome; Young Adult	2013
Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:5 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Spain; Time Factors; Treatment Outcome	2014
[Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2013, Volume: 33, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies	2013
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PloS one, 2014, Volume: 9, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Gene Frequency; Genetic Variation; Genotype; HLA Antigens; HLA-B Antigens; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptors, KIR; Receptors, KIR3DL1; Treatment Outcome	2014
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. BMC complementary and alternative medicine, 2014, Mar-30, Volume: 14 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Dacarbazine; Disease Progression; Drugs, Chinese Herbal; Female; Glioblastoma; Herb-Drug Interactions; Humans; Irinotecan; Liver; Middle Aged; Phytotherapy; Temozolomide	2014
Low-dose irinotecan improves advanced lupus nephritis in mice potentially by changing DNA relaxation and anti-double-stranded DNA binding. Arthritis & rheumatology (Hoboken, N.J.), 2014, Volume: 66, Issue:8 Topics: Animals; Camptothecin; Disease Progression; DNA; Female; Irinotecan; Lupus Nephritis; Mice; Mice, Inbred NZB; Topoisomerase I Inhibitors	2014
[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2014, Volume: 36, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Esophagogastric Junction; Fatigue; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab	2014
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma. Oncotarget, 2014, May-15, Volume: 5, Issue:9 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Survival Rate	2014
CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Cancer medicine, 2014, Volume: 3, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tomography, X-Ray Computed; Treatment Outcome	2014
Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World journal of gastroenterology, 2014, Aug-21, Volume: 20, Issue:31 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome	2014
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jan-01, Volume: 33, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome; Tumor Burden	2015
Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis. Journal of neuro-oncology, 2015, Volume: 121, Issue:3 Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Disease Progression; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Retrospective Studies; Young Adult	2015
Extrapulmonary small cell carcinoma in head and neck. The Journal of laryngology and otology, 2015, Volume: 129 Suppl 2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Combinations; Etoposide; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Radiotherapy, Adjuvant; Survival Rate; Tegafur	2015
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World journal of gastroenterology, 2015, Feb-21, Volume: 21, Issue:7 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2015
FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance. Molecular cancer, 2015, Apr-28, Volume: 14 Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzodioxoles; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Indolizines; Irinotecan; Lung Neoplasms; Mice, SCID; Neoplasm Proteins; Topoisomerase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays	2015
Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma. Journal of pediatric hematology/oncology, 2015, Volume: 37, Issue:6 Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retreatment; Retrospective Studies; Salvage Therapy	2015
Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo. Cancer medicine, 2015, Volume: 4, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Comet Assay; Disease Progression; DNA Damage; DNA Repair; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Genetic; Repetitive Sequences, Nucleic Acid; Topoisomerase I Inhibitors; Treatment Outcome	2015
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. American journal of clinical oncology, 2016, Volume: 39, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome	2016
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience. Hepato-gastroenterology, 2014, Volume: 61, Issue:131 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome	2014
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer. Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drosophila Proteins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nerve Tissue Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Rate; Transcription Factors; Treatment Outcome	2016
Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer. International journal of oncology, 2016, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Progression; Female; HCT116 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Male; Middle Aged; Phosphorylation; Retinoblastoma Protein; Retrospective Studies; RNA, Small Interfering	2016
[Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. Zhonghua wai ke za zhi [Chinese journal of surgery], 2016, Apr-01, Volume: 54, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Tertiary Care Centers; Treatment Outcome	2016
Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma? Cancer medicine, 2016, Volume: 5, Issue:7 Topics: Administration, Metronomic; Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Combined Modality Therapy; Disease Progression; Female; Glioma; Humans; Irinotecan; Maintenance Chemotherapy; Male; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retreatment; Retrospective Studies; Vinblastine	2016
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017, Volume: 19, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Spain; Survival Rate	2017
The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy. Journal of chemotherapy (Florence, Italy), 2017, Volume: 29, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Disease Progression; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Survival Rate; Thymidylate Synthase	2017
[Curative Resection for Chemorefractory Advanced Gastric Cancer with Pancreatic Invasion by Pancreatoduodenectomy - A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12 Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Neoplasm Invasiveness; Oxonic Acid; Pancreas; Pancreaticoduodenectomy; Stomach Neoplasms; Tegafur; Treatment Outcome	2016
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-01, Volume: 14, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Magnesium; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome	2008
The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice. Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Skin; Skin Diseases; Weight Loss	2008
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2 Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Irinotecan; Italy; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome	2009
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-20, Volume: 26, Issue:33 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Rate	2008
Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology, 2009, Volume: 250, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Palliative Care; Prospective Studies; Survival Rate; Tomography, Spiral Computed	2009
Chemotherapy for small-bowel Adenocarcinoma at a single institution. Surgery today, 2009, Volume: 39, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Vitamin B Complex	2009
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:7 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Survival Rate; Time Factors; Treatment Outcome	2009
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; Treatment Outcome	2009
[Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Progression; Humans; Immunotherapy; Irinotecan; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab; Treatment Outcome	2009
Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. Expert opinion on biological therapy, 2009, Volume: 9, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk; Smoking; Treatment Outcome	2009
Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin. Diseases of the colon and rectum, 2009, Volume: 52, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chi-Square Distribution; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Logistic Models; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Survival Rate	2009
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cause of Death; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Fluorouracil; Humans; Irinotecan; Middle Aged; Multicenter Studies as Topic; Netherlands; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies	2010
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:2 Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Odds Ratio; Retrospective Studies; Survival Analysis; Treatment Outcome	2010
Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3 Topics: Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Platinum Compounds; Survival Analysis; Taxoids; Vinblastine; Vinorelbine	2010
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy]. Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:9 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Child; Colonic Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Rectal Neoplasms; Remission Induction; Young Adult	2009
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10 Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Gene Frequency; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Quality of Life; Survival Analysis; Time Factors; Treatment Outcome	2009
UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World journal of gastroenterology, 2009, Oct-28, Volume: 15, Issue:40 Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Retrospective Studies	2009
Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer investigation, 2010, Volume: 28, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Time Factors; Treatment Failure	2010
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie, 2010, Volume: 33, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cetuximab; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Rate	2010
Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Apr-15, Volume: 16, Issue:8 Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Blotting, Western; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Disease Progression; DNA-Binding Proteins; Female; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Irinotecan; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tissue Array Analysis; Topoisomerase I Inhibitors; Treatment Outcome; Tumor Cells, Cultured	2010
[Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Squamous Cell; Survival Rate; Uterine Cervical Neoplasms	2010
Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing. Onkologie, 2010, Volume: 33, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome	2010
[Utility of CPT-11 as salvage chemotherapy for progressive or recurrent breast cancer patients with multiple drug resistance]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:6 Topics: Adult; Aged; Breast Neoplasms; Camptothecin; Diarrhea; Disease Progression; Drug Resistance, Multiple; Humans; Irinotecan; Middle Aged; Neutropenia; Recurrence; Salvage Therapy	2010
Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. The pharmacogenomics journal, 2011, Volume: 11, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Genotype; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome	2011
Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2010, Volume: 13, Issue:3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Confidence Intervals; Disease Progression; Drug Combinations; Female; Health Status Indicators; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Time Factors; Treatment Failure	2010
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. Journal of neuro-oncology, 2011, Volume: 103, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide	2011
Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. British journal of cancer, 2010, Nov-09, Volume: 103, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Genotype; Humans; Irinotecan; Neoplasm Metastasis; Pharmacogenetics; Survival Analysis; Time Factors; Vascular Endothelial Growth Factor A	2010
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. British journal of cancer, 2010, Nov-09, Volume: 103, Issue:10 Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Blood Cell Count; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Creatinine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hemoglobins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Patient Selection	2010
Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients. Clinics and research in hepatology and gastroenterology, 2011, Volume: 35, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome	2011
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome	2011
A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms	2011
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. British journal of cancer, 2011, May-24, Volume: 104, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; DNA Methylation; Female; Genes, erbB-1; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Promoter Regions, Genetic; Treatment Outcome	2011
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction. Clinical colorectal cancer, 2011, Mar-01, Volume: 10, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin	2011
Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience. Clinical colorectal cancer, 2011, Mar-01, Volume: 10, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Risk; Survival Analysis; Vitamin B Complex	2011
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI. Anticancer research, 2011, Volume: 31, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A	2011
Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Diagnosis, Differential; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Analysis; Thymus Neoplasms; Treatment Outcome	2011
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology, 2011, Volume: 80, Issue:5-6 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure; Treatment Outcome	2011
Irinotecan as a second-line monotherapy for small cell lung cancer. Asian Pacific journal of cancer prevention : APJCP, 2011, Volume: 12, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome	2011
Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro-oncology, 2012, Volume: 14, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diagnostic Imaging; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult	2012
Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases. Annals of surgical oncology, 2012, Volume: 19, Issue:9 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Colorectal Neoplasms; Contraindications; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Tumor Burden	2012
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anti-cancer drugs, 2012, Volume: 23, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Compassionate Use Trials; Dacarbazine; Disease Progression; Glioma; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome	2012
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis. American journal of clinical oncology, 2013, Volume: 36, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome	2013
Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2013, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Retrospective Studies	2013
Irinotecan during pregnancy in metastatic colon cancer. Tumori, 2012, Volume: 98, Issue:6 Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cesarean Section; Colectomy; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Gestational Age; Humans; Infant, Newborn; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Treatment Failure	2012
Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult	2013
Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen. Onkologie, 2002, Volume: 25, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Thiophenes; Treatment Failure	2002
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen. British journal of cancer, 2002, Oct-07, Volume: 87, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Esophageal Neoplasms; Female; Gastrointestinal Diseases; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Treatment Outcome	2002
Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Remission Induction	2003
Validation of the role of angiogenesis as a chemotherapeutic target. Clinical colorectal cancer, 2003, Volume: 3, Issue:2 Topics: Adaptation, Physiological; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Fluorouracil; Humans; Irinotecan; Leucovorin; Neovascularization, Pathologic; Randomized Controlled Trials as Topic; Survival Analysis; Wound Healing	2003
Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients. Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Progression; Drug Resistance, Neoplasm; Humans; Ileal Neoplasms; Irinotecan; Jejunal Neoplasms; Male; Salvage Therapy; Survival Analysis; Treatment Outcome	2003
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids	2004
An immediate hemolytic reaction induced by repeated administration of oxaliplatin. Transfusion, 2004, Volume: 44, Issue:6 Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Blood Transfusion; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Disease Progression; Fatal Outcome; Female; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin	2004
Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer. Oncology reports, 2004, Volume: 12, Issue:2 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Clinical Laboratory Techniques; Collagen; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gels; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Recurrence; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome	2004
[Evaluation of bronchial arterial infusion (BAI) for metastatic lung tumor from colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Camptothecin; Cisplatin; Colorectal Neoplasms; Disease Progression; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Length of Stay; Lung Neoplasms; Male; Middle Aged	2004
Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer. Anti-cancer drugs, 2005, Volume: 16, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome	2005
[Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy]. MMW Fortschritte der Medizin, 2004, Nov-18, Volume: 146, Issue:47 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Immunotherapy; Irinotecan; Male; Mutation; Neoplasms; Prostatic Neoplasms; Research; Simplexvirus; Trastuzumab; Vascular Endothelial Growth Factor A	2004
Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Annals of surgical oncology, 2005, Volume: 12, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Disease Progression; Female; Humans; Hyperthermia, Induced; Irinotecan; Liver Neoplasms; Male; Melphalan; Middle Aged; Neoplasm Staging; Treatment Failure; Treatment Outcome	2005
[Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2006, Volume: 57, Issue:8 Topics: Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Folliculitis; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Skin	2006
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. Oncology, 2005, Volume: 68, Issue:2-3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome	2005
Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs; Rectal Neoplasms; Retrospective Studies; Survival Rate	2005
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Oncology, 2005, Volume: 69, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronotherapy; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome	2005
Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. The Korean journal of internal medicine, 2005, Volume: 20, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local	2005
Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2006, Volume: 10, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colonic Neoplasms; Disease Progression; Hepatic Artery; Humans; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Mitomycin; Rectal Neoplasms; Remission Induction; Starch; Stomach Neoplasms; Topoisomerase I Inhibitors	2006
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan. European journal of haematology, 2006, Volume: 76, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome	2006
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine	2006
A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. Cancer research, 2006, Aug-01, Volume: 66, Issue:15 Topics: Animals; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Female; Humans; Image Processing, Computer-Assisted; Irinotecan; Luciferases; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneal Neoplasms; Photons; Stomach Neoplasms; Transfection	2006
Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. British journal of cancer, 2007, Feb-26, Volume: 96, Issue:4 Topics: Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Camptothecin; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Disease Progression; Drug Resistance, Neoplasm; Drug Utilization; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; National Health Programs; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Practice Patterns, Physicians'; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Sex Distribution; Survival Analysis	2007
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Eruptions; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; NF-kappa B; Survival Rate	2007
Bi-weekly irinotecan hydrochloride and cisplatin as a second-line chemotherapy for patients with advanced gastric cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:13 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Stomach Neoplasms; Survival Rate; Treatment Outcome	2007
Cetuximab efficacy in patients treated routinely in university hospitals. Gastroenterologie clinique et biologique, 2007, Volume: 31, Issue:11 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; France; Hospitals, University; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Registries	2007
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-10, Volume: 26, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis	2008
Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Survival Rate	2008
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. British journal of cancer, 2008, Feb-26, Volume: 98, Issue:4 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Dihydrouracil Dehydrogenase (NADP); Disease Progression; DNA Primers; DNA-Binding Proteins; Drug Combinations; Endonucleases; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxonic Acid; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Survival Rate; Tegafur	2008
Carboxylesterase 2 is downregulated in colorectal cancer following progression of the disease. Cancer investigation, 2008, Volume: 26, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Blotting, Western; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Disease Progression; Down-Regulation; Humans; Immunoglobulin G; Irinotecan; Mice; Neoplasm Staging; Topoisomerase I Inhibitors	2008
Bevacizumab plus irinotecan in recurrent glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-20, Volume: 26, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local	2008
Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-15, Volume: 14, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Retrospective Studies	2008
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9 Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genetic Markers; Haplotypes; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Salvage Therapy; Signal Transduction	2008
"Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009, Volume: 35, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drainage; Female; Fluorouracil; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Seeding; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Care; Retrospective Studies; Treatment Outcome	2009
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. Journal of neuro-oncology, 2008, Volume: 89, Issue:1 Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Hemorrhage; Child; Child, Preschool; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Glioma; Humans; Irinotecan; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome	2008
Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). American journal of clinical oncology, 1997, Volume: 20, Issue:5 Topics: Adenine; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Codon; Colonic Neoplasms; Disease Progression; DNA, Neoplasm; Drug Resistance, Neoplasm; Exons; Female; Fluorouracil; Forecasting; Genes, ras; Guanine; Humans; Irinotecan; Male; Middle Aged; Mutation; Prognosis; Retreatment; Sequence Analysis, DNA; Survival Rate; Thymine; Treatment Failure	1997
Second line therapies move to the forefront in colorectal cancer. Journal of the National Cancer Institute, 1999, Jun-16, Volume: 91, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome	1999
[Irinotecan--experience with second-line treatment in advanced colorectal cancer] . Orvosi hetilap, 2000, Aug-13, Volume: 141, Issue:33 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Genes, MDR; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Topoisomerase I Inhibitors; Treatment Failure; Treatment Outcome	2000
Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure. Onkologie, 2002, Volume: 25, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Irinotecan; Kidney Failure, Chronic; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Renal Dialysis	2002
Influence of phenytoin on the disposition of irinotecan: a case report. Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:2 Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Disease Progression; Drug Interactions; Enzyme Induction; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Melphalan; Mixed Function Oxygenases; Neoplasm Recurrence, Local; Ondansetron; Phenobarbital; Phenytoin; Pineal Gland; Pinealoma; Prodrugs; Salvage Therapy; Seizures	2002